Key facts
- This page summarizes William Ho's Form 4 filing for RAPT Therapeutics, Inc. (RAPT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2025, 16:21.
William Ho - 20 Jun 2025 Form 4 Insider Report for RAPT Therapeutics, Inc. (RAPT)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- RAPT
- Reported as of
- 20 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2025, 16:21:48 UTC
- Prior SEC filing
- 03 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rodney Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William Ho filed Form 4 for RAPT Therapeutics, Inc. (RAPT) on 24 Jun 2025.
Change
- Previous filing in this sequence was filed on 03 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001400901
Primary reporting owner
HO WILLIAM
- Relationship
- CHIEF MEDICAL OFFICER
- Address
- C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO
- Signature
- /s/ Rodney Young, Attorney-in-Fact
- Signature date
- 24 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RAPT
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 20 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $7.43
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.